Eikon Therapeutics Inc (EIKN)

Jun 15, 2026

Soros opened a brand new EIKN position — moomoo's New tab ca...moomoo Community - Moomoo

Jun 15, 2026

Jun 12, 2026

Eikon Therapeutics: Initiating Coverage With A Cautious Buy Rating (NASDAQ:EIKN) - Seeking Alpha

Jun 12, 2026

Jun 12, 2026

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Jun 12, 2026

Jun 11, 2026

IPO Tracker 2026: Kardigan stitches up $369M IPO plan - BioSpace

Jun 11, 2026

Jun 11, 2026

Eikon Therapeutics Appoints Ma. Fatima Francisco to Board - The Globe and Mail

Jun 11, 2026

Jun 10, 2026

New director and stock option grant at Eikon Therapeutics (NASDAQ: EIKN) - Stock Titan

Jun 10, 2026

Jun 08, 2026

Eikon Therapeutics discloses new USP1 inhibitors - BioWorld News

Jun 08, 2026

Jun 08, 2026

Eikon Therapeutics, Inc. Announces Appointment of Ma. Fatima D. Francisco as Independent Director and Compensation Committee Member, Effective June 15, 2026 - marketscreener.com

Jun 08, 2026

Jun 08, 2026

Eikon Therapeutics appoints Francisco to board of directors By Investing.com - Investing.com Nigeria

Jun 08, 2026

Jun 08, 2026

Eikon Therapeutics appoints Francisco to board of directors - Investing.com India

Jun 08, 2026

Jun 08, 2026

Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors - Yahoo Finance

Jun 08, 2026

Jun 03, 2026

Eikon Therapeutics, Inc. Stock 12‑Month Price Target Cut to $24.8, Implies 158% Upside - TradingView

Jun 03, 2026

Jun 03, 2026

BofA Securities Maintains Eikon Therapeutics(EIKN.US) With Buy Rating, Cuts Target Price to $32 - Moomoo

Jun 03, 2026

Jun 02, 2026

Cantor Fitzgerald reiterates Overweight on Eikon stock By Investing.com - Investing.com Australia

Jun 02, 2026

Jun 02, 2026

Cantor Fitzgerald reiterates Overweight on Eikon stock - Investing.com UK

Jun 02, 2026

Jun 01, 2026

Eikon Therapeutics 2026 Pipeline Update: Promising Clinical Results for TLR7/8, PARP1, and WRN Inhibitors in Oncology - Minichart

Jun 01, 2026

Jun 01, 2026

Eikon Therapeutics (EIKN) highlights EIK1001 NSCLC and EIK1003 solid tumor data at ASCO 2026 - Stock Titan

Jun 01, 2026

May 31, 2026

J.P. Morgan Maintains Eikon Therapeutics(EIKN.US) With Buy Rating - Moomoo

May 31, 2026

May 30, 2026

Eikon Therapeutics, Inc.Common Stock (Nasdaq:EIKN) Stock Quote - The Chronicle-Journal

May 30, 2026

May 30, 2026

Eikon Therapeutics reports promising Phase 2 NSCLC and Phase 1/2 solid tumor trial data at ASCO 2026 - Pluang

May 30, 2026

May 30, 2026

Eikon Therapeutics Completes Enrollment for Phase 2 TeLuRide-005 Trial of EIK1001 in Stage 4 NSCLC and Reports Promising Clinical Data for EIK1003 - Quiver Quantitative

May 30, 2026

May 30, 2026

Experimental Eikon drugs show responses in advanced lung and ovarian cancer - Stock Titan

May 30, 2026

May 22, 2026

Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology - The Manila Times

May 22, 2026

May 21, 2026

Eikon to present clinical data on three cancer programs at ASCO - Investing.com UK

May 21, 2026

May 21, 2026

Eikon Therapeutics to present six abstracts on cancer drug trials at 2026 ASCO meeting - Pluang

May 21, 2026

May 21, 2026

Eikon Therapeutics Announces Presentation of Advanced Clinical Data at 2026 ASCO Annual Meeting - Quiver Quantitative

May 21, 2026

May 21, 2026

Eikon Therapeutics Announces Availability of Six Abstracts - GlobeNewswire

May 21, 2026

May 21, 2026

EIKN SEC FilingsEikon Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan

May 21, 2026

May 15, 2026

Number of shareholders of Eikon Therapeutics, Inc. – NASDAQ:EIKN - TradingView

May 15, 2026

May 15, 2026

Innovation Endeavors reports 3.37M shares in Eikon Therapeutics (EIKN) - Stock Titan

May 15, 2026

May 15, 2026

BofA Securities Maintains Eikon Therapeutics(EIKN.US) With Buy Rating, Maintains Target Price $34 - Moomoo

May 15, 2026

May 15, 2026

EIKN Should I Buy - Intellectia AI

May 15, 2026

May 13, 2026

Roger Perlmutter holds 2.89M shares of Eikon Therapeutics (NASDAQ: EIKN) - Stock Titan

May 13, 2026

May 12, 2026

Wedbush Maintains Eikon Therapeutics(EIKN.US) With Sell Rating, Cuts Target Price to $5 - Moomoo

May 12, 2026

May 12, 2026

Wedbush Cuts Price Target on Eikon Therapeutics to $5 From $7, Keeps Underperform Rating - marketscreener.com

May 12, 2026

May 12, 2026

Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates - Sahm

May 12, 2026

May 11, 2026

Eikon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 11, 2026

May 11, 2026

IPO cash lifts Eikon Therapeutics (NASDAQ: EIKN) to $596M - Stock Titan

May 11, 2026

May 11, 2026

Eikon Therapeutics (Nasdaq: EIKN) details Q1 loss and ASCO 2026 data plans - Stock Titan

May 11, 2026

May 11, 2026

Press Release: Eikon Therapeutics Reports First Quarter 2026 Financial Results and Provides Clinical Updates - Moomoo

May 11, 2026

May 06, 2026

FMR LLC holds 3.84M EIKON Therapeutics shares (NASDAQ: EIKN) - Stock Titan

May 06, 2026

May 02, 2026

Eikon Therapeutics prices upsized IPO at $18 per share By Investing.com - Investing.com Nigeria

May 02, 2026

Apr 29, 2026

[SCHEDULE 13G] Eikon Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan

Apr 29, 2026